Authors :
Aditya Barih Farhan; Nancy Margarita Rehatta
Volume/Issue :
Volume 6 - 2021, Issue 10 - October
Google Scholar :
http://bitly.ws/gu88
Scribd :
https://bit.ly/3CxoWpM
Abstract :
The prevalence of chronic pain ranges
from 30-50% in patients. A comprehensive pain scale
assessment must be carried out because of the high rate
of morbidity, opioid dependence, and failure of
conventional treatment. Objective pain measurement is
expected to improve the quality of chronic pain
management for malignancy. This study is aim to
explore the kynurenic acid level serum in different type
of cancer based on its origin, thus we can further
evaluate the pain of cancer therapy based on its origin.
Methods: This is a literature review study using
electronic database between the years 2011 to 2021. We
used Pubmed, Google Scholar, Web of Science databases
and analyzed the datas in to comprehensive resumes.
Results: Twenty-five articles, identified from 140
abstracts, were included in this review. From the articles
we explored kynurenic acid was found in the serum of
cancer patients in the range from 21.3 to 250 nM
depending on the type of cancer. It is increasing in some
kind of cancer, except for primary cervical cancer than
healthy people. The level of this biomarker for example
colon adenocarcinoma (37.52 nmol/L, lung
Adenocarcinoma (107.1 nmol/L), and multiple myeloma
(59.23 nmol/L). Kynurenic acid can be a plasma
biomarkers of inflammation and kynurenine pathway
activity are independent predictors of cancer mortality
and the latter can be used as progostotic factors.
Conclusion: Kynurenic acid level was different in every
cancer origin. It is hypothesized that the biological
behaviour of type of cancer alter the action of
kynurenine metabolic pathway
Keywords :
Kynurenic Acid, Pain, Biomarker, Cancer
The prevalence of chronic pain ranges
from 30-50% in patients. A comprehensive pain scale
assessment must be carried out because of the high rate
of morbidity, opioid dependence, and failure of
conventional treatment. Objective pain measurement is
expected to improve the quality of chronic pain
management for malignancy. This study is aim to
explore the kynurenic acid level serum in different type
of cancer based on its origin, thus we can further
evaluate the pain of cancer therapy based on its origin.
Methods: This is a literature review study using
electronic database between the years 2011 to 2021. We
used Pubmed, Google Scholar, Web of Science databases
and analyzed the datas in to comprehensive resumes.
Results: Twenty-five articles, identified from 140
abstracts, were included in this review. From the articles
we explored kynurenic acid was found in the serum of
cancer patients in the range from 21.3 to 250 nM
depending on the type of cancer. It is increasing in some
kind of cancer, except for primary cervical cancer than
healthy people. The level of this biomarker for example
colon adenocarcinoma (37.52 nmol/L, lung
Adenocarcinoma (107.1 nmol/L), and multiple myeloma
(59.23 nmol/L). Kynurenic acid can be a plasma
biomarkers of inflammation and kynurenine pathway
activity are independent predictors of cancer mortality
and the latter can be used as progostotic factors.
Conclusion: Kynurenic acid level was different in every
cancer origin. It is hypothesized that the biological
behaviour of type of cancer alter the action of
kynurenine metabolic pathway
Keywords :
Kynurenic Acid, Pain, Biomarker, Cancer